SLC41A3
gene geneOn this page
Also known as FLJ20473
Summary
SLC41A3 (solute carrier family 41 member 3, HGNC:31046) is a protein-coding gene on chromosome 3q21.2-q21.3, encoding Solute carrier family 41 member 3 (Q96GZ6). Na(+)/Mg(2+) ion exchanger that acts as a predominant Mg(2+) efflux system at the mitochondrial inner membrane.
Enables magnesium:sodium antiporter activity. Involved in mitochondrial magnesium ion transmembrane transport. Located in mitochondrial inner membrane and plasma membrane.
Source: NCBI Gene 54946 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 106 total
- MANE Select transcript:
NM_017836
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:31046 |
| Approved symbol | SLC41A3 |
| Name | solute carrier family 41 member 3 |
| Location | 3q21.2-q21.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ20473 |
| Ensembl gene | ENSG00000114544 |
| Ensembl biotype | protein_coding |
| OMIM | 610803 |
| Entrez | 54946 |
Gene structure
Transcript identifiers
Ensembl transcripts: 36 — 29 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay
ENST00000315891, ENST00000346785, ENST00000360370, ENST00000383598, ENST00000504035, ENST00000504118, ENST00000505996, ENST00000506102, ENST00000507008, ENST00000507280, ENST00000508835, ENST00000509064, ENST00000509452, ENST00000510651, ENST00000512470, ENST00000512557, ENST00000513464, ENST00000513723, ENST00000514023, ENST00000514333, ENST00000514677, ENST00000514891, ENST00000910125, ENST00000910126, ENST00000910127, ENST00000910128, ENST00000910129, ENST00000910130, ENST00000910131, ENST00000947432, ENST00000947433, ENST00000947434, ENST00000947435, ENST00000947436, ENST00000947437, ENST00000947438
RefSeq mRNA: 5 — MANE Select: NM_017836
NM_001008485, NM_001008486, NM_001008487, NM_001164475, NM_017836
CCDS: CCDS33842, CCDS33843, CCDS33844, CCDS43144, CCDS54635
Canonical transcript exons
ENST00000360370 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001559606 | 126084093 | 126084124 |
| ENSE00002084619 | 126006357 | 126007225 |
| ENSE00003462142 | 126015494 | 126015573 |
| ENSE00003478742 | 126008732 | 126008880 |
| ENSE00003602380 | 126012615 | 126012749 |
| ENSE00003642951 | 126026335 | 126026479 |
| ENSE00003656958 | 126022786 | 126022932 |
| ENSE00003671645 | 126050943 | 126051050 |
| ENSE00003680006 | 126067947 | 126068246 |
| ENSE00003685678 | 126033607 | 126033678 |
| ENSE00003692093 | 126016731 | 126016875 |
Expression profiles
Bgee: expression breadth ubiquitous, 273 present calls, max score 96.17.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1359 / max 87.0869, expressed in 1767 samples.
FANTOM5 promoters (9 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 44314 | 6.7813 | 1745 |
| 44316 | 1.9078 | 1085 |
| 44315 | 0.1491 | 30 |
| 44312 | 0.1348 | 48 |
| 44317 | 0.1251 | 70 |
| 44309 | 0.0153 | 3 |
| 44313 | 0.0152 | 10 |
| 44311 | 0.0044 | 2 |
| 44310 | 0.0030 | 2 |
Top tissues by expression
286 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right hemisphere of cerebellum | UBERON:0014890 | 96.17 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 96.08 | gold quality |
| cerebellar cortex | UBERON:0002129 | 96.05 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 95.14 | gold quality |
| cerebellum | UBERON:0002037 | 95.13 | gold quality |
| left ovary | UBERON:0002119 | 95.07 | gold quality |
| prefrontal cortex | UBERON:0000451 | 95.06 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 95.06 | gold quality |
| cingulate cortex | UBERON:0003027 | 95.02 | gold quality |
| right frontal lobe | UBERON:0002810 | 94.97 | gold quality |
| right ovary | UBERON:0002118 | 94.80 | gold quality |
| thoracic aorta | UBERON:0001515 | 94.72 | gold quality |
| ascending aorta | UBERON:0001496 | 94.70 | gold quality |
| right testis | UBERON:0004534 | 94.36 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 94.19 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 94.19 | gold quality |
| left testis | UBERON:0004533 | 94.13 | gold quality |
| cortical plate | UBERON:0005343 | 94.11 | gold quality |
| body of uterus | UBERON:0009853 | 94.01 | gold quality |
| aorta | UBERON:0000947 | 93.99 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 93.95 | gold quality |
| left adrenal gland | UBERON:0001234 | 93.89 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 93.86 | gold quality |
| right coronary artery | UBERON:0001625 | 93.68 | gold quality |
| amygdala | UBERON:0001876 | 93.68 | gold quality |
| adenohypophysis | UBERON:0002196 | 93.64 | gold quality |
| right adrenal gland | UBERON:0001233 | 93.62 | gold quality |
| neocortex | UBERON:0001950 | 93.60 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 93.60 | gold quality |
| popliteal artery | UBERON:0002250 | 93.55 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-4850 | no | 189.77 |
| E-GEOD-99795 | no | 89.79 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
22 targeting SLC41A3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-651-3P | 99.94 | 73.48 | 5177 |
| HSA-MIR-338-5P | 99.92 | 72.34 | 2951 |
| HSA-MIR-12119 | 99.87 | 68.35 | 1653 |
| HSA-MIR-4799-5P | 99.82 | 70.60 | 2663 |
| HSA-MIR-12130 | 99.75 | 65.47 | 452 |
| HSA-MIR-4649-3P | 99.56 | 66.90 | 1783 |
| HSA-MIR-6852-5P | 99.17 | 66.69 | 2073 |
| HSA-MIR-6814-5P | 99.03 | 66.68 | 1273 |
| HSA-MIR-6760-5P | 98.87 | 66.73 | 1515 |
| HSA-MIR-2467-3P | 98.65 | 67.18 | 1969 |
| HSA-MIR-6878-5P | 98.49 | 67.91 | 2142 |
| HSA-MIR-6864-5P | 98.38 | 66.59 | 1079 |
| HSA-MIR-6511B-5P | 97.98 | 65.64 | 823 |
| HSA-MIR-6811-5P | 97.98 | 64.96 | 848 |
| HSA-MIR-12127 | 97.93 | 66.67 | 793 |
| HSA-MIR-3920 | 97.75 | 69.02 | 1168 |
| HSA-MIR-4253 | 97.48 | 65.11 | 692 |
| HSA-MIR-6862-5P | 97.48 | 64.84 | 713 |
| HSA-MIR-509-3-5P | 97.21 | 67.74 | 1517 |
| HSA-MIR-509-5P | 97.21 | 67.90 | 1512 |
Literature-anchored findings (GeneRIF, showing 2)
- Data identify SLC41A3 as the first mammalian mitochondrial Mg(2+) efflux system, which greatly enhances the understanding of intracellular Mg(2+) homeostasis. (PMID:27302215)
- SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma. (PMID:34819993)
Cross-species orthologs
7 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | slc41a3 | ENSDARG00000061272 |
| mus_musculus | Slc41a3 | ENSMUSG00000030089 |
| rattus_norvegicus | Slc41a3 | ENSRNOG00000045821 |
| drosophila_melanogaster | CG33181 | FBGN0053181 |
| caenorhabditis_elegans | ZK1053.6 | WBGENE00014201 |
| caenorhabditis_elegans | WBGENE00019504 | |
| caenorhabditis_elegans | WBGENE00022682 |
Paralogs (2): SLC41A1 (ENSG00000133065), SLC41A2 (ENSG00000136052)
Protein
Protein identifiers
Solute carrier family 41 member 3 — Q96GZ6 (reviewed: Q96GZ6)
All UniProt accessions (11): D6R925, D6R9M9, D6R9S7, D6R9X6, D6RC02, D6RDB0, D6RDM3, D6RF72, D6RHE3, D6RJC0, Q96GZ6
UniProt curated annotations — full annotation on UniProt →
Function. Na(+)/Mg(2+) ion exchanger that acts as a predominant Mg(2+) efflux system at the mitochondrial inner membrane.
Subcellular location. Mitochondrion inner membrane.
Similarity. Belongs to the SLC41A transporter family.
Isoforms (9)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q96GZ6-1 | 1 | yes |
| Q96GZ6-2 | 2 | |
| Q96GZ6-3 | 3 | |
| Q96GZ6-4 | 4 | |
| Q96GZ6-5 | 5 | |
| Q96GZ6-6 | 6 | |
| Q96GZ6-7 | 7 | |
| Q96GZ6-8 | 8 | |
| Q96GZ6-9 | 9 |
RefSeq proteins (5): NP_001008485, NP_001008486, NP_001008487, NP_001157947, NP_060306* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR006667 | SLC41_membr_dom | Domain |
| IPR036739 | SLC41_membr_dom_sf | Homologous_superfamily |
| IPR045349 | SLC41A1-3 | Family |
Pfam: PF01769
Catalyzed reactions (Rhea), 1 shown:
- Mg(2+)(in) + 2 Na(+)(out) = Mg(2+)(out) + 2 Na(+)(in) (RHEA:66616)
UniProt features (30 total): transmembrane region 10, splice variant 10, sequence conflict 5, sequence variant 2, chain 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96GZ6-F1 | 79.10 | 0.42 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 109 (showing top):
GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_MAGNESIUM_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, GOCC_MITOCHONDRIAL_ENVELOPE, chr3q21, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_SODIUM_ION_TRANSPORT, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOCC_ORGANELLE_INNER_MEMBRANE, GOMF_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_MONOATOMIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_SECONDARY_ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, DODD_NASOPHARYNGEAL_CARCINOMA_DN
GO Biological Process (8): mitochondrial magnesium ion transmembrane transport (GO:0045016), monoatomic ion transport (GO:0006811), monoatomic cation transport (GO:0006812), magnesium ion transport (GO:0015693), metal ion transport (GO:0030001), sodium ion transmembrane transport (GO:0035725), transmembrane transport (GO:0055085), monoatomic cation transmembrane transport (GO:0098655)
GO Molecular Function (5): magnesium:sodium antiporter activity (GO:0061768), protein binding (GO:0005515), monoatomic cation transmembrane transporter activity (GO:0008324), magnesium ion transmembrane transporter activity (GO:0015095), obsolete inorganic cation transmembrane transporter activity (GO:0022890)
GO Cellular Component (4): mitochondrial inner membrane (GO:0005743), plasma membrane (GO:0005886), mitochondrion (GO:0005739), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| magnesium ion transmembrane transport | 2 |
| transport | 2 |
| monoatomic cation transport | 2 |
| monoatomic cation transmembrane transport | 2 |
| monoatomic ion transport | 1 |
| metal ion transport | 1 |
| sodium ion transport | 1 |
| cellular process | 1 |
| monoatomic ion transmembrane transport | 1 |
| sodium ion transmembrane transporter activity | 1 |
| magnesium ion transmembrane transporter activity | 1 |
| metal cation:monoatomic cation antiporter activity | 1 |
| binding | 1 |
| monoatomic ion transmembrane transporter activity | 1 |
| metal ion transmembrane transporter activity | 1 |
| organelle inner membrane | 1 |
| mitochondrial membrane | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cytoplasm | 1 |
| intracellular membrane-bounded organelle | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
540 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SLC41A3 | TRPM6 | Q9BX84 | 791 |
| SLC41A3 | MRS2 | Q9HD23 | 695 |
| SLC41A3 | CNNM2 | Q9H8M5 | 688 |
| SLC41A3 | TRPM7 | Q96QT4 | 679 |
| SLC41A3 | SPRYD7 | Q5W111 | 600 |
| SLC41A3 | MAGT1 | Q9H0U3 | 597 |
| SLC41A3 | MMGT1 | Q8N4V1 | 519 |
| SLC41A3 | CNNM3 | Q8NE01 | 515 |
| SLC41A3 | CNNM1 | Q9NRU3 | 515 |
| SLC41A3 | CLDN16 | Q9Y5I7 | 512 |
| SLC41A3 | CNNM4 | Q6P4Q7 | 512 |
| SLC41A3 | FXYD2 | P54710 | 504 |
| SLC41A3 | NIPAL3 | Q6P499 | 498 |
| SLC41A3 | SLC12A3 | P55017 | 492 |
| SLC41A3 | CLDN19 | Q8N6F1 | 490 |
IntAct
53 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SLC41A3 | REL | psi-mi:“MI:0915”(physical association) | 0.560 |
| NHERF4 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| REL | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC41A3 | NHERF4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC41A3 | SUFU | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCL3L1 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ARLN | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMBIM6 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| IGFBP5 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC41A3 | SMCO4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PLP1 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TSPO2 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC41A3 | BDNF | psi-mi:“MI:0915”(physical association) | 0.560 |
| GAPDH | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC41A3 | CCR2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| SLC41A3 | GPR37 | psi-mi:“MI:0915”(physical association) | 0.370 |
| SLC41A3 | NPSR1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| SLC41A3 | SMO | psi-mi:“MI:0915”(physical association) | 0.370 |
| MAPK6 | SLC41A3 | psi-mi:“MI:0915”(physical association) | 0.370 |
| SLC41A3 | CREB3 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ZDHHC12 | NBAS | psi-mi:“MI:0914”(association) | 0.350 |
| ZACN | FAM234B | psi-mi:“MI:0914”(association) | 0.350 |
| HTR3A | EXTL3 | psi-mi:“MI:0914”(association) | 0.350 |
| OR13J1 | FZD7 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (104): SLC41A3 (Two-hybrid), PDZD3 (Two-hybrid), SLC41A3 (Affinity Capture-MS), SLC41A3 (Reconstituted Complex), SLC41A3 (Two-hybrid), SLC41A3 (Affinity Capture-MS), SLC41A3 (Affinity Capture-MS), SLC41A3 (Affinity Capture-MS), SLC41A3 (Affinity Capture-MS), SLC41A3 (Affinity Capture-RNA), SLC41A3 (Proximity Label-MS), SLC41A3 (Two-hybrid), SLC41A3 (Two-hybrid), IGFBP5 (Two-hybrid), PLP1 (Two-hybrid)
ESM2 similar proteins: A0A075B734, A1L272, A2IBY8, A8W649, A9Y006, D4A7H1, E7EXX2, F7B113, O14520, O35454, O54794, O62735, O94956, P34080, P35525, P41181, P47862, P47863, P47864, P51789, P51797, P56402, P56403, P79099, Q06495, Q06496, Q08DE6, Q4R691, Q5PQL3, Q62052, Q866S3, Q8BLV3, Q8BXB6, Q8BZ00, Q8IVB4, Q8K078, Q8MIQ9, Q8R2N1, Q8TCT8, Q921R8
Diamond homologs: E7EXX2, Q3SWT5, Q4R335, Q5R839, Q5ZHX6, Q6DFC0, Q8BJA2, Q8BYR8, Q8IVJ1, Q921R8, Q96GZ6, Q96JW4
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
106 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 64 |
| Likely benign | 7 |
| Benign | 14 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1705 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:126008726:GCTTA:G | donor_gain | 1.0000 |
| 3:126008727:CTTAC:C | donor_gain | 1.0000 |
| 3:126008728:TTAC:T | donor_loss | 1.0000 |
| 3:126008728:TTACC:T | donor_gain | 1.0000 |
| 3:126008729:TA:T | donor_loss | 1.0000 |
| 3:126008729:TACCT:T | donor_gain | 1.0000 |
| 3:126008730:A:AC | donor_gain | 1.0000 |
| 3:126008730:A:C | donor_gain | 1.0000 |
| 3:126008730:ACC:A | donor_loss | 1.0000 |
| 3:126008731:C:CC | donor_gain | 1.0000 |
| 3:126008731:C:T | donor_gain | 1.0000 |
| 3:126008731:CCT:C | donor_loss | 1.0000 |
| 3:126008876:GATTT:G | acceptor_gain | 1.0000 |
| 3:126008877:ATTT:A | acceptor_gain | 1.0000 |
| 3:126008878:TTT:T | acceptor_gain | 1.0000 |
| 3:126008879:TT:T | acceptor_gain | 1.0000 |
| 3:126008881:C:CC | acceptor_gain | 1.0000 |
| 3:126008881:CTGAA:C | acceptor_loss | 1.0000 |
| 3:126008882:T:C | acceptor_loss | 1.0000 |
| 3:126015488:ACGT:A | donor_loss | 1.0000 |
| 3:126015491:TA:T | donor_loss | 1.0000 |
| 3:126015492:A:AT | donor_loss | 1.0000 |
| 3:126015493:C:CA | donor_loss | 1.0000 |
| 3:126015493:CCA:C | donor_gain | 1.0000 |
| 3:126015569:CGAAA:C | acceptor_gain | 1.0000 |
| 3:126015574:C:CC | acceptor_gain | 1.0000 |
| 3:126016726:CTCA:C | donor_loss | 1.0000 |
| 3:126016727:TCAC:T | donor_loss | 1.0000 |
| 3:126016728:CACC:C | donor_loss | 1.0000 |
| 3:126016729:A:T | donor_loss | 1.0000 |
AlphaMissense
3122 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:126012713:C:G | R336P | 0.997 |
| 3:126012715:G:C | S335R | 0.995 |
| 3:126012715:G:T | S335R | 0.995 |
| 3:126012717:T:G | S335R | 0.995 |
| 3:126022850:G:C | S227R | 0.994 |
| 3:126022850:G:T | S227R | 0.994 |
| 3:126022852:T:G | S227R | 0.994 |
| 3:126026372:G:C | S187R | 0.990 |
| 3:126026372:G:T | S187R | 0.990 |
| 3:126026374:T:G | S187R | 0.990 |
| 3:126012704:G:A | T339I | 0.989 |
| 3:126022842:T:G | D230A | 0.989 |
| 3:126026369:A:C | S188R | 0.989 |
| 3:126026369:A:T | S188R | 0.989 |
| 3:126026371:T:G | S188R | 0.989 |
| 3:126022808:G:C | S241R | 0.988 |
| 3:126022808:G:T | S241R | 0.988 |
| 3:126022810:T:G | S241R | 0.988 |
| 3:126050953:A:G | L124P | 0.988 |
| 3:126012698:A:G | L341P | 0.987 |
| 3:126016765:A:G | W286R | 0.987 |
| 3:126016765:A:T | W286R | 0.987 |
| 3:126016733:G:C | S296R | 0.986 |
| 3:126016733:G:T | S296R | 0.986 |
| 3:126016735:T:G | S296R | 0.986 |
| 3:126022842:T:C | D230G | 0.985 |
| 3:126022879:C:G | D218H | 0.984 |
| 3:126022842:T:A | D230V | 0.983 |
| 3:126026473:C:G | A154P | 0.983 |
| 3:126007180:A:G | W434R | 0.982 |
dbSNP variants (sampled 300 via entrez): RS1000052601 (3:126092324 C>T), RS1000083037 (3:126021324 G>A), RS1000171506 (3:126067531 C>T), RS1000232780 (3:126072042 T>C), RS1000243563 (3:126024184 A>G), RS1000250942 (3:126071695 A>T), RS1000282866 (3:126043913 G>A), RS1000430825 (3:126037614 T>C), RS1000436309 (3:126096466 C>T), RS1000448016 (3:126009252 G>A,T), RS1000483174 (3:126037380 T>C), RS1000522615 (3:126076935 C>T), RS1000532158 (3:126054926 C>T), RS1000533635 (3:126096829 T>G), RS1000641052 (3:126096672 C>T)
Disease associations
OMIM: gene MIM:610803 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST011354_15 | Bell’s palsy | 3.000000e-06 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: transporter — SLC41 family of divalent cation transporters
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation | 2 |
| Aflatoxin B1 | decreases expression, increases methylation | 2 |
| aristolochic acid I | decreases expression | 1 |
| FR900359 | decreases phosphorylation | 1 |
| bisphenol F | affects cotreatment, increases expression | 1 |
| potassium perchlorate | decreases expression | 1 |
| sodium arsenite | increases abundance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| bisphenol S | affects cotreatment, increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Resveratrol | decreases expression | 1 |
| Arsenic Trioxide | decreases expression | 1 |
| Arsenic | increases expression, increases abundance | 1 |
| Caffeine | decreases phosphorylation | 1 |
| Dexamethasone | affects cotreatment, increases expression | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
| Valproic Acid | decreases expression | 1 |
| Zearalenone | decreases expression | 1 |
| 1-Methyl-3-isobutylxanthine | affects cotreatment, increases expression | 1 |
| Cyclosporine | increases methylation | 1 |
| Antirheumatic Agents | increases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
Cellosaurus cell lines
5 cell lines: 4 cancer cell line, 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3HI | Abcam HEK293T SLC41A3 KO | Transformed cell line | Female |
| CVCL_D4P0 | HCT116-SLC41A3-KO-c10 | Cancer cell line | Male |
| CVCL_D4P1 | HCT116-SLC41A3-KO-c6 | Cancer cell line | Male |
| CVCL_TN68 | HAP1 SLC41A3 (-) 1 | Cancer cell line | Male |
| CVCL_TN69 | HAP1 SLC41A3 (-) 2 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): Bell’s palsy